Abstract

Summit Therapeutics PLC will report fiscal second-quarter results for the period ended June 30, 2026 on July 23, 2026 Post-Mkt; our preview highlights a zero-revenue profile with deeper operating losses, balanced against advancing ivonescimab milestones and predominantly bullish institutional sentiment.

Market Forecast

For the quarter ending June 30, 2026, current forecasts indicate revenue of 0.00 million US dollars (0% year over year), EPS of -0.28 (down 195.57% year over year), and EBIT of -196.49 million US dollars (down 170.70% year over year). Gross margin and net profit margin guidance for the quarter were not provided; consensus continues to anticipate immaterial revenue and a widened loss as spending supports late-stage development. The company’s ongoing operations remain concentrated in collaboration and licensing arrangements with minimal revenue contribution, while costs reflect trial execution and corporate expenses. The most promising segment is the ivonescimab development program; revenue contribution is currently 0.00 million US dollars (0% year over year), with performance tied to clinical and regulatory milestones rather than product sales.

Last Quarter Review

In the quarter ended March 31, 2026, Summit Therapeutics PLC reported revenue of 0.00 million US dollars (0% year over year), a gross margin not disclosed, a GAAP net loss attributable to shareholders of 189.40 million US dollars, a net profit margin not disclosed, and EPS of -0.24 (down 166.67% year over year). One notable financial highlight was the quarter-on-quarter change in net profit of 13.57%, reflecting the moving expense base amid trial and corporate spending. On the business side, revenue was immaterial and primarily associated with licensing activities, with the main-business breakdown indicating 0.71 million US dollars from license agreements; year-over-year growth for this item was not disclosed.

Current Quarter Outlook

Main operating drivers and reported revenue dynamics

The company is expected to again report negligible revenue for the quarter, consistent with its pre-commercial status and the minimal contribution from licensing and collaboration payments. Forecasts compiled for this preview point to revenue of 0.00 million US dollars, alongside an EPS estimate of -0.28 and EBIT of -196.49 million US dollars, as operating expenses continue to reflect late-stage clinical development and corporate costs. With gross margin and net profit margin not guided, investors will likely focus on the cadence of operating expenses versus cash runway and the potential timing of any non-dilutive inflows. Within the quarter, Summit Therapeutics PLC’s operating expense trend remains influenced by share-based compensation recognized in 2025 and ongoing trial costs. The prior quarter’s GAAP operating expenses of 195.21 million US dollars underscore the current investment phase; while the magnitude may fluctuate quarter to quarter, the direction for the near term remains elevated as pivotal programs move forward. Reported cash, cash equivalents, and short-term investments stood at 598.70 million US dollars at March 31, 2026, setting the context for burn-rate discussions and the need—timing dependent—for capital or partnership proceeds. While the business portfolio includes legacy anti-infective assets, these are no longer strategic priorities. On July 14, 2026, the company signed a divestiture agreement for ridinilazole, including a 0.50 million US dollar upfront and up to 104.50 million US dollars in regulatory and commercial milestones plus tiered royalties; given the signing date, the upfront is unlikely to be recognized in the period ended June 30, 2026. This means the current quarter’s revenue line is poised to remain near zero, with investors instead parsing expense sustainability and pipeline progress.

Ivonescimab program trajectory and quarterly implications

Ivonescimab remains the central value driver. During the quarter, the program benefitted from Phase III HARMONi-6 overall survival results presented on May 31, 2026, which showed a survival advantage versus an active comparator regimen in advanced squamous non-small cell lung cancer; the dataset also aligned with previously announced progression-free survival success. Even with the strength of the survival signal, investor reaction has been mixed, reflecting questions about the generalizability of China-led data to broader global populations and the regulatory bridge to the United States and Europe. Separately, the company has disclosed that its biologics license application for ivonescimab plus chemotherapy in previously treated EGFR-mutated non-squamous NSCLC was accepted with a PDUFA goal date of November 14, 2026. This milestone anchors the regulatory calendar but carries limited direct effect on the current quarter’s financials. In addition, the HARMONi-3 squamous cohort is expected to deliver final progression-free survival data in the second half of 2026, following an interim analysis earlier in the year that did not meet the statistical success threshold, a factor that continues to shape sentiment and expectations. For the present quarter, the most relevant financial implication is continued R&D investment to support pivotal and combinational studies. The program’s breadth—with external collaborations that include combinations in RAS-mutant tumors and an anticipated GSK combination study—reinforces the near-term cost footprint as Summit Therapeutics PLC advances toward potential approvals next year. Market participants will be sensitive to any commentary on clinical timelines, regulatory interactions, and the strategy for US and European datasets that could mitigate concerns raised by strictly China-based trials.

Stock-price drivers this quarter: cash, financing posture, and catalysts

The financial setup is an important near-term variable. On June 10, 2026, Summit Therapeutics PLC announced an underwritten public offering of 500.00 million US dollars of common stock with an option for an additional 75.00 million US dollars; on June 11, 2026, the company withdrew the proposed offering due to market conditions. This sequence highlights both the capital intensity of the development plan and the sensitivity of the equity market to financing risk, which can weigh on the shares even without actual dilution. The company’s quarter-end cash position will be a focal point in the July 23, 2026 release as investors assess the implied runway against operating expenses that in the prior quarter totaled 195.21 million US dollars. Given the withdrawal of the offering, management’s commentary on alternative financing paths—be it non-dilutive transactions, milestone receipts, or later resubmission when conditions are favorable—will likely be parsed closely. The ridinilazole divestment announced July 14, 2026 illustrates one avenue for monetizing non-core assets, though the near-term financial impact is modest and the timing of milestone recognition remains event-dependent. Clinical and regulatory catalysts remain the principal share-price levers. The HARMONi-6 overall survival data provided a supportive clinical narrative, but investor uncertainty persists around global applicability and competitive landscapes, including antibody-drug conjugates in lung cancer. Meanwhile, the accepted BLA with a defined PDUFA timeline provides visibility into potential 2026 commercialization scenarios, which may not be directly reflected in the current quarter’s numbers but sets the longer-term value proposition around which analysts frame their targets. In the interim, the market will anchor on expense discipline, balance-sheet flexibility, and clarity around the late-2026 regulatory path.

What matters most in the print

Three items are poised to matter most in the quarter’s release. First, confirmation that revenue remains effectively zero and that the EPS and EBIT loss tracks within the range of expectations will frame the financial base case. Second, the operating expense and cash trajectory—relative to March 31, 2026 levels—will inform the implied runway and shape views on timing and form of any future capital actions. Third, management’s qualitative update on the ivonescimab clinical plan—particularly steps taken to address geography and comparator questions for Western regulators—can influence sentiment even absent new data within the quarter. Investors will also watch for any additional business development comments or small, non-dilutive inflows that could help smooth the cash profile without near-term equity issuance. Although the ridinilazole transaction is strategically consistent with portfolio focus, the recognition of proceeds is unlikely to move the needle this quarter. The strategic direction remains centered on converting late-stage oncology assets into regulatory approvals in 2026, with the current quarter serving as a checkpoint on execution and funding.

Key takeaways on business mix and growth potential

The reported business mix this quarter should remain concentrated in licensing and collaboration activity, with revenue immaterial and not expected to deviate from the 0.00 million US dollars baseline. In that context, gross margin and net margin discussion is largely moot in the absence of product sales; investors instead translate operating metrics through the lens of expense control and the pace of clinical advancement. The largest growth potential is clearly tied to ivonescimab; while its near-term revenue is zero with 0% year-over-year change, the magnitude of future value hinges on regulatory outcomes and competitive dynamics over the next 12–18 months. By design, cost investment precedes revenue recognition in this model. The interplay between expenses, cash runway, and potential financing remains central to valuation in the pre-commercial phase. The company’s ability to secure favorable terms for collaborations and asset monetizations, as well as to navigate capital markets opportunistically, can help bridge to potential commercialization beyond 2026.

Analyst Opinions

The majority of recent institutional views collected over the last six months are bullish, with Buy ratings outweighing neutral stances. Evercore ISI reiterated a Buy with a 34.00 US dollars price target and highlights the longer-term opportunity tied to ivonescimab’s late-stage profile and the program’s survival data presented during the quarter. Wells Fargo has maintained a Buy and a 30.00 US dollars target, emphasizing the clinical momentum and potential for regulatory de-risking as the program advances toward significant 2026 milestones. Citi has also maintained a Buy as a supportive voice around the near-term catalyst path, citing continued investor interest around data readouts and the regulatory timeline. On the other side, Jefferies maintained a Hold with a 17.00 US dollars target, and one firm shifted to Neutral in May, citing increased competitive pressure in lung cancer from antibody-drug conjugates and the implications of an interim analysis in HARMONi-3 that did not cross a statistical threshold. That said, explicit bearish calls have been limited in the period reviewed; thus, bullish views constitute the clear majority in our collected sample. The bullish cohort’s thesis converges on several points: HARMONi-6’s overall survival benefit as supportive of the asset’s clinical profile; the accepted BLA with a November 14, 2026 PDUFA providing a tangible regulatory anchor; and the potential for subsequent combinations and indications to broaden the opportunity set post-approval. From an earnings-preview standpoint, these analysts generally expect another quarter of minimal revenue and a deeper loss that is largely a function of planned R&D and corporate investment. Their focus remains on the durability and translatability of the ivonescimab data and the company’s execution against the regulatory calendar. In the near term, they anticipate that the balance-sheet discussion and any signals on capital strategy could influence trading more than the P&L line items themselves. In aggregate, bullish opinions dominate, supported by the clinical trajectory and defined regulatory milestones, with the earnings event serving primarily to update cash and expense contours rather than to showcase product revenue inflection.